IS7500A - thurrdufts samsetningar - Google Patents

thurrdufts samsetningar

Info

Publication number
IS7500A
IS7500A IS7500A IS7500A IS7500A IS 7500 A IS7500 A IS 7500A IS 7500 A IS7500 A IS 7500A IS 7500 A IS7500 A IS 7500A IS 7500 A IS7500 A IS 7500A
Authority
IS
Iceland
Prior art keywords
dry powder
powder formulations
formulations
dry
powder
Prior art date
Application number
IS7500A
Other languages
English (en)
Inventor
Charles Roche Trevor
Arvind Bulsara Pallav
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS7500A publication Critical patent/IS7500A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS7500A 2002-04-13 2004-10-11 thurrdufts samsetningar IS7500A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0208608.0A GB0208608D0 (en) 2002-04-13 2002-04-13 Composition
PCT/GB2003/001542 WO2003088943A1 (en) 2002-04-13 2003-04-10 Dry powder compositions

Publications (1)

Publication Number Publication Date
IS7500A true IS7500A (is) 2004-10-11

Family

ID=9934855

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7500A IS7500A (is) 2002-04-13 2004-10-11 thurrdufts samsetningar

Country Status (19)

Country Link
US (1) US20050244340A1 (is)
EP (1) EP1494644A1 (is)
JP (1) JP2005530733A (is)
KR (1) KR20040099436A (is)
CN (1) CN1658839A (is)
AR (1) AR039409A1 (is)
AU (1) AU2003217073A1 (is)
BR (1) BR0309114A (is)
CA (1) CA2481467A1 (is)
GB (1) GB0208608D0 (is)
IL (1) IL164420A0 (is)
IS (1) IS7500A (is)
MX (1) MXPA04010080A (is)
NO (1) NO20044497L (is)
PL (1) PL373294A1 (is)
RU (1) RU2004130439A (is)
TW (1) TW200404008A (is)
WO (1) WO2003088943A1 (is)
ZA (1) ZA200408245B (is)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002333644A1 (en) 2001-09-17 2003-04-01 Glaxo Group Limited Dry powder medicament formulations
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
EP1643974A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Inhalable pharmaceutical formulations comprising a sugar ester
EP1643973A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
WO2006066907A1 (en) * 2004-12-21 2006-06-29 Glaxo Group Limited Pharmaceutical formulations
RU2007133547A (ru) * 2005-02-10 2009-03-20 Глаксо Груп Лимитед (GB) Способы получения лактозы с использованием методов предварительной сортировки и приготовляемые из нее фармацевтические композиции
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
DK2046787T3 (da) 2006-08-01 2011-07-18 Glaxo Group Ltd Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
KR20160003183A (ko) * 2013-04-29 2016-01-08 사노피 에스에이 흡입식 약학적 조성물 및 그를 포함하는 흡입기 장치
AU2015296024A1 (en) * 2014-08-01 2017-03-23 Luxena Pharmaceuticals, Inc. Palonosetron formulations and uses thereof
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
CN110237373B (zh) * 2018-03-08 2023-06-02 润生药业有限公司 一种生产用于联合用药的药物载体的装置及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8007911A (pt) * 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
SE448277B (sv) * 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
NO166268C (no) * 1985-07-30 1991-07-03 Glaxo Group Ltd Innretning for administrering av medikamenter til pasienter.
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
JPH04220268A (ja) * 1990-12-19 1992-08-11 Olympus Optical Co Ltd バルーンカテーテル
US6517860B1 (en) * 1996-12-31 2003-02-11 Quadrant Holdings Cambridge, Ltd. Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
AU8229998A (en) * 1997-07-03 1999-01-25 Quadrant Holdings Cambridge Limited Modified glycosides, compositions comprised thereof and methods of use thereof
US6352722B1 (en) * 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
CA2347856C (en) * 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
GB9916316D0 (en) * 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0020616D0 (en) * 2000-08-21 2000-10-11 Quadrant Holdings Cambridge Particulates
WO2002043750A2 (en) * 2000-12-01 2002-06-06 Battelle Memorial Institute Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
ZA200408245B (en) 2007-03-28
NO20044497L (no) 2004-11-15
US20050244340A1 (en) 2005-11-03
AU2003217073A1 (en) 2003-11-03
MXPA04010080A (es) 2004-12-13
RU2004130439A (ru) 2005-06-10
TW200404008A (en) 2004-03-16
EP1494644A1 (en) 2005-01-12
BR0309114A (pt) 2005-02-01
AR039409A1 (es) 2005-02-16
WO2003088943A1 (en) 2003-10-30
PL373294A1 (en) 2005-08-22
GB0208608D0 (en) 2002-05-22
JP2005530733A (ja) 2005-10-13
CN1658839A (zh) 2005-08-24
CA2481467A1 (en) 2003-10-30
KR20040099436A (ko) 2004-11-26
IL164420A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
DK1689360T3 (da) Tørpulverformuleringer
NO20035251D0 (no) Törrpulverinhalator
DK3536344T3 (da) Superfin formoterolformulering
PT1501534E (pt) Formulacoes farmaceuticas
FR2842417B1 (fr) Composition cosmetique
FR2842416B1 (fr) Composition cosmetique
IS8309A (is) Lyfjablöndur
ATE460955T1 (de) Trockenpulver-inhalator
DE60118496D1 (de) Pulverzusammensetzung
DE60311307D1 (de) Shampoo-zusammensetzungen
NO20043418L (no) Stabiliserte adenovirusformuleringer
DE60310914D1 (de) Pulverzusammensetzung
IS7501A (is) thurrdufts innöndunar samsetning
DK1561472T3 (da) Faststofsammensætning
DK1596870T3 (da) Höjdosis-iblandronatformulering
DK1539089T3 (da) Reducerede aerosol-genererende formuleringer
IS7500A (is) thurrdufts samsetningar
DE60221611D1 (de) Trockenpulverinhalator
IS7582A (is) Hraðlosandi lyfjablanda
ITMI20011532A0 (it) Cosmetico solido
DE60326900D1 (de) Duftstoff-Zusammensetzung
DE60318421D1 (de) Trockenhefe-komposition
DE60123539D1 (de) Puderquaste
GB0218194D0 (en) Solid formulations
DK1567135T3 (da) Tiotropiumholdig pulverformulering til inhalation